Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis-Reference-Cited by-同舟云学术

Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis

Published:2022-07 Issue: Volume:63 Page:103814
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Zappulo Emanuela,Buonomo Antonio Riccardo,Moccia Marcello,Pinchera Biagio,Villari Riccardo,Petracca Maria,Lanzillo Roberta,Scotto Riccardo,Carotenuto Antonio,Viceconte Giulio,Schiano Moriello Nicola,Bruno Luca,Gentile Ivan,Brescia Morra Vincenzo

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference22 articles.

1. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis;Buonomo;Expert Opin. Drug Saf.,2018

2. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis;Buonomo;Mult. Scler. Relat. Disord.,2019

3. Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies;Buonomo;Expert Opin. Drug Saf.,2021

4. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study;Buonomo;J. Neurol.,2022

5. Infections in patients with multiple sclerosis: a national cohort study in Sweden;Castelo-Branco;Mult. Scler Relat. Disord.,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment;Journal of Neurology;2023-10-31

2. Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study;Neurology and Therapy;2022-06-02